当前位置:首页 - 行情中心 - 联亚药业(301569) - 财务分析

联亚药业

(301569)

  

流通市值:0.00万  总市值:0.00万
流通股本:0.00万   总股本:0.00万

联亚药业(301569)财务分析

利润表
报告期2026-06-302026-03-312025-12-312025-09-30
营业总收入491,831,812.75234,677,000895,470,048.65632,635,700
营业总成本323,570,067.89-616,368,836.41-
其他经营收益
营业利润164,172,332.5373,153,800262,832,229.95-
利润总额164,359,529.5673,284,200263,132,532.16-
净利润141,027,688.95-227,819,038.04-
每股收益
其他综合收益-681,513.46--488,396.77-
综合收益总额140,346,175.49-227,330,641.27-
资产负债表
报告期2026-06-302026-03-312025-12-312025-06-30
流动资产:
流动资产合计1,753,931,477.68-1,618,746,549.071,421,738,156.06
非流动资产:
非流动资产合计675,083,874.11-675,104,154.05673,052,078.6
资产总计2,429,015,351.792,340,071,2002,293,850,703.122,094,790,234.66
流动负债:
流动负债合计133,757,828.77-166,642,364.64141,607,670.19
非流动负债:
非流动负债合计114,660,394.2-117,213,380.4596,897,627.43
负债合计248,418,222.97252,144,300283,855,745.09238,505,297.62
所有者权益(或股东权益):
归属于母公司股东权益合计2,180,597,128.822,087,926,8002,009,994,958.031,856,284,937.04
股东权益合计2,180,597,128.82-2,009,994,958.031,856,284,937.04
负债和股东权益合计2,429,015,351.79-2,293,850,703.122,094,790,234.66
现金流量表
报告期2026-06-302026-03-312025-12-312025-06-30
经营活动产生的现金流量:
经营活动现金流入小计520,607,883.71-903,225,586.73437,858,546.4
经营活动现金流出小计317,251,181.97-580,647,004.32295,686,105.36
经营活动产生的现金流量净额203,356,701.74112,550,500322,578,582.41142,172,441.04
投资活动产生的现金流量:
投资活动现金流入小计2,172,219,633.52-3,616,618,641.351,625,057,160.44
投资活动现金流出小计2,453,083,859.68-3,858,859,423.551,769,772,774.58
投资活动产生的现金流量净额-280,864,226.16--242,240,782.2-144,715,614.14
筹资活动产生的现金流量:
筹资活动现金流入小计----
筹资活动现金流出小计1,537,830-72,703,129.370,127,087.42
筹资活动产生的现金流量净额-1,537,830--72,703,129.3-70,127,087.42
汇率变动对现金及现金等价物的影响-15,401,271.61--18,271,678-3,086,345
现金及现金等价物净增加额-94,446,626.03--10,637,007.09-75,756,605.52
期末现金及现金等价物余额128,661,864.05-223,108,490.08157,988,891.65
补充资料:
现金及现金等价物的净增加额-94,446,626.03--10,637,007.09-75,756,605.52
TOP↑